Travere Therapeutics Stock Analysis

Travere Stock Analysis Notes

About 99.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 4.07. Travere Therapeutics had not issued any dividends in recent years. The entity had 1:9 split on the 8th of November 2011. Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California. Travere Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 310 people. To find out more about Travere Therapeutics contact Eric Dube at 888 969 7879 or learn more at https://www.travere.com.

Travere Therapeutics Investment Alerts

Travere Therapeutics Upcoming and Recent Events

Travere Largest EPS Surprises

View All Earnings Estimates

Travere Therapeutics Environmental, Social, and Governance (ESG) Scores

Travere Stock Institutional Investors

Note, although Travere Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Travere Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.83 B.

Travere Profitablity

The company has Profit Margin (PM) of (1.38) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.79) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.79.

Management Efficiency

Travere Therapeutics has return on total asset (ROA) of (0.2315) % which means that it has lost $0.2315 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.4675) %, meaning that it created substantial loss on money invested by shareholders. Travere Therapeutics' management efficiency ratios could be used to measure how well Travere Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.69 in 2025. Return On Capital Employed is likely to rise to -0.77 in 2025. At this time, Travere Therapeutics' Non Currrent Assets Other are fairly stable compared to the past year. Intangible Assets is likely to rise to about 138.4 M in 2025, whereas Total Assets are likely to drop slightly above 474.5 M in 2025.

Technical Drivers

As of the 26th of February, Travere Therapeutics has the Coefficient Of Variation of 1088.09, semi deviation of 2.51, and Risk Adjusted Performance of 0.0754. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Travere Therapeutics, as well as the relationship between them.

Travere Therapeutics Price Movement Analysis

Travere Therapeutics Insider Trading Activities

Travere Therapeutics Outstanding Bonds

Travere Therapeutics Predictive Daily Indicators

Travere Therapeutics Corporate Filings

Travere Therapeutics Forecast Models

Travere Therapeutics' time-series forecasting models are one of many Travere Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Travere Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Travere Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Travere shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Travere Therapeutics. By using and applying Travere Stock analysis, traders can create a robust methodology for identifying Travere entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Travere analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Travere analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Travere Therapeutics stock analysis indicators help investors evaluate how Travere Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Travere Therapeutics shares will generate the highest return on investment. By understating and applying Travere Therapeutics stock analysis, traders can identify Travere Therapeutics position entry and exit signals to maximize returns.

When running Travere Therapeutics' price analysis, check to measure Travere Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Travere Therapeutics is operating at the current time. Most of Travere Therapeutics' value examination focuses on studying past and present price action to predict the probability of Travere Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Travere Therapeutics' price. Additionally, you may evaluate how the addition of Travere Therapeutics to your portfolios can decrease your overall portfolio volatility.